首页|低分子肝素联合硫酸镁和静脉营养支持对胎儿生长受限的效果

低分子肝素联合硫酸镁和静脉营养支持对胎儿生长受限的效果

扫码查看
目的 分析低分子肝素联合硫酸镁和静脉营养支持治疗对胎儿生长受限(FGR)的效果。方法 回顾性分析浙江省杭州市富阳区妇幼保健院自2021年11月至2024年1月收治的145例FGR孕妇,根据治疗方法将其分为2组,硫酸镁联合静脉营养支持治疗为对照组,低分子肝素联合硫酸镁、静脉营养支持治疗为观察组,连续用药5d;比较2组胎儿生长发育指标、脐动脉血流动力学指标及围生儿指标,并评价用药安全性。结果 治疗后,与对照组相比,观察组双顶径、头围、腹围、股骨长均更高(t=6。655、7。466、2。485、24。565,P均<0。05);治疗后,观察组收缩期与舒张期流速比(S/D值)、阻力指数(RI)、搏动指数(PI)均较对照组更低(t=5。790、5。058、5。639,P均<0。05);观察组分娩孕周、新生儿体质量、胎盘质量均较对照组高(t=7。542、16。692、16。043,P均<0。05),2组1 min、5 min新生儿Apgar评分比较差异无统计学意义(t=1。150、0。530,P均>0。05);治疗期间未发生过敏反应、血小板减少、凝血功能障碍等并发症。结论 低分子肝素联合硫酸镁和静脉营养支持治疗FGR能有效促进胎儿生长发育,改善胎儿脐动脉血流动力学,改善胎儿结局。
Effects of low-molecular-weight heparin combined with magnesium sulfate and intravenous nutrition on fetal growth restriction
Objective To analyze the effects of low-molecular-weight heparin combined with magnesium sulfate and intravenous nutrition on fetal growth restriction (FGR).Methods A retrospective analysis was con-ducted on a total of 145 pregnant women with fetal growth restriction (FGR) admitted to Hangzhou Fuyang Women and Children Hospital from November 2021 to January 2024.They were divided into a control group and an ob-servation group based on different treatment methods.The control group received magnesium sulfate combined with intravenous nutritional support therapy,while the observation group received low-molecular-weight heparin combined with magnesium sulfate and intravenous nutritional support therapy.Both groups were treated for 5 days.The fetal growth and development indicators,umbilical artery hemodynamic indicators,and perinatal indicators were compared between the two groups,and the safety of medication was evaluated.Results After treatment,the biparietal diameter,head circumference,abdominal circumference,and femur length in the observation group were significantly higher than those in the control group (t=6.655,7.466,2.485,24.565,all P<0.05);and the systolic to diastolic velocity ratio (S/D value),resistance index (RI),and pulsatility index (PI) in the observation group were significantly lower (t=5.790,5.058,5.639,all P<0.05).The gestational age at delivery,neonatal weight,and pla-cental weight in the observation group were significantly higher (t=7.542,16.692,16.043,all P<0.05).There were no significant differences in 1-min and 5-min Apgar scores between the two groups (t=1.150,0.530,P>0.05).No complications such as allergic reactions,thrombocytopenia,or coagulation disorders occurred during treatment.Conclusion The treatment of FGR with low-molecular-weight heparin combined with magnesium sulfate and in-travenous nutrition can effectively promote fetal growth and development,improve fetal umbilical artery hemody-namics,and improve fetal outcomes.

Fetal growth retardationMagnesium sulfatePregnant women

孙莉莉、李亚男、吴丹青

展开 >

杭州市富阳区妇幼保健院妇产科,浙江杭州 311400

胎儿生长迟缓 硫酸镁 孕妇

2024

中国药物与临床
中国医院协会

中国药物与临床

影响因子:0.846
ISSN:1671-2560
年,卷(期):2024.24(23)